AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Upside 433%
Price (€) 2.15
Market Cap (€M) 78.5
Perf. 1W: 10.3%
Perf. 1M: -37.1%
Perf. 3M: -59.5%
Perf Ytd: -56.7%
10 day relative perf. to stoxx600: -2.72%
20 day relative perf. to stoxx600: -36.6%
Other news/comments23/10/2018

Bond conversion


Crossject has announced that Gemme Venture, the company’s main shareholder, had converted 100% of the convertible bonds (869,565) it had subscribed to in July, at a price of €1.4892, thus leading to the creation of 591,304 new shares (+6.3%) and raising its stake to 24.3% (from c.20%).


The news confirms the confidence of Gemme Venture in the business model and translates into a c. €880k strengthening of shareholders’ funds, which reached €2.35m at the end of June 2018.


No major change to our numbers after the news. The extra dilution is compensated by a lower level of net debt, of course, and as such the conversion does not much change our numbers/valuation, which are once again essentially driven by future prospects.


28 Nov 18 Financing issue
A €3.9m capital increase

23 Oct 18 Other news/comments
Bond conversion

27 Sep 18 Earnings/sales releases
H1 18: insignificant; some more time needed to ...

05 Sep 18 Target Change
On its way to reaching the market

17 May 18 Latest
Business update

22 Mar 18 Earnings/sales releases
On its way to reach the market…